Provided by Tiger Fintech (Singapore) Pte. Ltd.

Neurocrine Biosciences

133.46
-1.4600-1.08%
Post-market: 133.460.00000.00%19:21 EDT
Volume:724.78K
Turnover:96.92M
Market Cap:13.21B
PE:45.13
High:135.00
Open:134.00
Low:132.10
Close:134.92
Loading ...

Ingrid Delaet, Chief Regulatory Officer, Reports Disposal of Common Shares in Neurocrine Biosciences Inc

Reuters
·
Yesterday

Chief Scientific Officer Jude Onyia Reports Disposal of Common Shares in Neurocrine Biosciences Inc

Reuters
·
Yesterday

Neurocrine Biosciences’ Phase 2 Study on NBI-1117568 for Schizophrenia: Key Updates

TIPRANKS
·
Yesterday

Buy Rating for Neurocrine Biosciences Inc. Driven by Crenessity Launch and Discounted Valuation

TIPRANKS
·
10 Jul

Neurocrine Biosciences Inc. to Announce Second Quarter 2025 Financial Results

Reuters
·
10 Jul

UBS Adjusts Price Target on Neurocrine Biosciences to $174 From $152, Maintains Buy Rating

MT Newswires Live
·
10 Jul

Neurocrine Is Maintained at Buy by UBS

Dow Jones
·
09 Jul

Neurocrine price target raised to $174 from $152 at UBS

TIPRANKS
·
09 Jul

Neurocrine Biosciences Inc. Chief Scientific Officer Jude Onyia Reports Disposal of Common Shares

Reuters
·
08 Jul

RBC Capital Remains a Buy on Neurocrine (NBIX)

TIPRANKS
·
08 Jul

RBC Raises Price Target on Neurocrine Biosciences to $146 From $145, Keeps Outperform Rating

MT Newswires Live
·
07 Jul

Neurocrine initiates Phase 1 study of NBIP-01435

TIPRANKS
·
01 Jul

Neurocrine Biosciences Initiates Phase 1 Clinical Study for NBIP-01435, a New Long-Acting CRF1 Receptor Antagonist for Congenital Adrenal Hyperplasia

Reuters
·
01 Jul

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Nbip-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist

THOMSON REUTERS
·
01 Jul

Neurocrine Biosciences Unveils Promising Results from KINECT-HD Study Showcasing INGREZZA®'s Efficacy in Reducing Huntington's Disease Chorea Burden

Reuters
·
27 Jun

Neurocrine Biosciences Presents New Post-Hoc Data Analyses From Kinect®-Hd Study Demonstrating Significant Reduction in Disease Burden With Ingrezza® (Valbenazine) Capsules for Huntington's Disease Chorea

THOMSON REUTERS
·
27 Jun

Neurocrine presents new data on patient-reported improvements with INGREZZA

TIPRANKS
·
20 Jun

Neurocrine Biosciences Inc. to Present New Data on INGREZZA® at American Association of Nurse Practitioners National Conference

Reuters
·
20 Jun

S&P 500 Futures Up In Premarket Trading; Regencell Bioscience, EchoStar Lead

Dow Jones
·
16 Jun

Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer

THOMSON REUTERS
·
10 Jun